Clinical Research and Molecular Diagnostics Unit, National Public Health Laboratory, Ministry of Health, Juba, Republic of South Sudan.
Parasitology Unit, National Public Health Laboratory, Ministry of Health, Juba, Republic of South Sudan.
PLoS One. 2018 Oct 10;13(10):e0205383. doi: 10.1371/journal.pone.0205383. eCollection 2018.
The SD BIOLINE HIV/Syphilis Duo assay is the first World Health Organization prequalified dual rapid diagnostic test for simultaneous detection of HIV and Treponema pallidum antibodies in human blood. Prior to introducing the test into antenatal clinics across South Sudan, a field evaluation of its clinical performance in diagnosing both HIV and syphilis in pregnant women was conducted. SD Bioline test performance on venous blood samples was compared with (i) Vironostika HIV1/2 Uniform II Ag/Ab reference standard and Alere Determine HIV 1/2 non-reference standard for HIV diagnosis, and (ii) Treponema pallidum hemagglutination reference standard and Rapid plasma reagin non-reference standard for syphilis. Sensitivity, specificity, positive predictive value (PPN), negative predictive value (NPV) and kappa (κ) value were calculated for each component against the reference standards within 95% confidence intervals (CIs); agreements between Determine HIV 1/2 and SD Bioline HIV tests were also calculated. Of 442 pregnant women recruited, eight (1.8%) were HIV positive, 22 (5.0%) had evidence of syphilis exposure; 14 (3.2%) had active infection. For HIV diagnosis, the sensitivity, specificity, PPV and NPV were 100% (95% CI: 63.1-100), 100% (95% CI: 99.2-100), 100% (95% CI: 63.1-100) and 100% (95% CI: 99.2-100) respectively with κ value of 1 (95% CI: 0.992-1.000). Overall agreement of the Duo HIV component and Determine test was 99.1% (95% CI: 0.977-0.998) with 66.7% (95% CI: 34.9-90.1) positive and 100% (95% CI: 0.992-1.000) negative percent agreements. For syphilis, the Duo assay sensitivity was 86.4% (95% CI: 65.1-97.1) and specificity 100% (95% CI: 99.1-100) with PPV 100% (95% CI: 82.4-100), NPV 99.2% (95% CI: 97.9-99.9) and κ value 0.92 (95% CI: 0.980-0.999). Our findings suggest the SD Bioline HIV/Syphilis Duo Assay could be suitable for HIV and syphilis testing in women attending antenatal services across South Sudan. Women with positive syphilis results should receive treatment immediately, whereas HIV positive women should undergo confirmatory testing following national HIV testing guidelines.
SD BIOLINE HIV/Syphilis Duo 检测试剂盒是世界卫生组织首次预认证的双重快速诊断检测试剂,可同时检测人血中的 HIV 和梅毒螺旋体抗体。在将该检测试剂盒引入南苏丹各地的产前诊所之前,对其在诊断孕妇 HIV 和梅毒中的临床性能进行了现场评估。SD Bioline 检测试剂盒对静脉血样本的检测性能与(i)Vironostika HIV1/2 Uniform II Ag/Ab 参考标准和 Alere Determine HIV 1/2 非参考标准进行了比较,用于 HIV 诊断,以及(ii)梅毒螺旋体血凝参考标准和快速血浆反应素非参考标准用于梅毒诊断。在 95%置信区间(CI)内,针对参考标准计算了每个成分的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和kappa(κ)值;还计算了 Determine HIV 1/2 和 SD Bioline HIV 检测之间的一致性。在招募的 442 名孕妇中,有 8 名(1.8%)HIV 阳性,22 名(5.0%)有梅毒暴露证据;14 名(3.2%)有活动性感染。对于 HIV 诊断,敏感性、特异性、PPV 和 NPV 分别为 100%(95%CI:63.1-100)、100%(95%CI:99.2-100)、100%(95%CI:63.1-100)和 100%(95%CI:99.2-100),κ 值为 1(95%CI:0.992-1.000)。Duo HIV 成分和 Determine 检测的总体一致性为 99.1%(95%CI:0.977-0.998),阳性符合率为 66.7%(95%CI:34.9-90.1),阴性符合率为 100%(95%CI:0.992-1.000)。对于梅毒,Duo 检测试剂盒的敏感性为 86.4%(95%CI:65.1-97.1),特异性为 100%(95%CI:99.1-100),PPV 为 100%(95%CI:82.4-100),NPV 为 99.2%(95%CI:97.9-99.9),κ 值为 0.92(95%CI:0.980-0.999)。我们的研究结果表明,SD Bioline HIV/Syphilis Duo 检测试剂盒可能适合南苏丹各地产前服务机构的 HIV 和梅毒检测。梅毒检测呈阳性的妇女应立即接受治疗,而 HIV 检测呈阳性的妇女应按照国家 HIV 检测指南进行确认检测。